These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 7960107)
1. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Moran EE; Brandt BL; Zollinger WD Infect Immun; 1994 Dec; 62(12):5290-5. PubMed ID: 7960107 [TBL] [Abstract][Full Text] [Related]
2. Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development. Rune Andersen S; Kolberg J; Høiby EA; Namork E; Caugant DA; Oddvar Frøholm L; Jantzen E; Bjune G Microb Pathog; 1997 Sep; 23(3):139-55. PubMed ID: 9281472 [TBL] [Abstract][Full Text] [Related]
3. Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B. Schmiel DH; Moran EE; Keiser PB; Brandt BL; Zollinger WD Infect Immun; 2011 Oct; 79(10):4146-56. PubMed ID: 21768280 [TBL] [Abstract][Full Text] [Related]
4. Enzyme linked immunosorbent assay (ELISA) for the detection of serum antibodies to the inner core lipopolysaccharide of Neisseria meningitidis group B. Plested JS; Gidney MA; Coull PA; Griffiths HG; Herbert MA; Bird AG; Richards JC; Moxon ER J Immunol Methods; 2000 Apr; 237(1-2):73-84. PubMed ID: 10725453 [TBL] [Abstract][Full Text] [Related]
5. Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines. Andersen SR; Bjune G; Lyngby J; Bryn K; Jantzen E Microb Pathog; 1995 Sep; 19(3):159-68. PubMed ID: 8559044 [TBL] [Abstract][Full Text] [Related]
6. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Moe GR; Zuno-Mitchell P; Lee SS; Lucas AH; Granoff DM Infect Immun; 2001 Jun; 69(6):3762-71. PubMed ID: 11349041 [TBL] [Abstract][Full Text] [Related]
7. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Mandrell RE; Zollinger WD Infect Immun; 1989 May; 57(5):1590-8. PubMed ID: 2468608 [TBL] [Abstract][Full Text] [Related]
8. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Zollinger WD; Moran EE; Devi SJ; Frasch CE Infect Immun; 1997 Mar; 65(3):1053-60. PubMed ID: 9038315 [TBL] [Abstract][Full Text] [Related]
9. Electromorphic characterization and description of conserved epitopes of the lipooligosaccharides of group A Neisseria meningitidis. Kim JJ; Mandrell RE; Hu Z; Westerink MA; Poolman JT; Griffiss JM Infect Immun; 1988 Oct; 56(10):2631-8. PubMed ID: 2458319 [TBL] [Abstract][Full Text] [Related]
10. Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis. Skevakis L; Frasch CE; Zahradnik JM; Dolin R J Infect Dis; 1984 Mar; 149(3):387-96. PubMed ID: 6425422 [TBL] [Abstract][Full Text] [Related]
12. Human bactericidal antibody response to meningococcal outer membrane protein vaccines. Zollinger WD; Boslego J; Frøholm LO; Ray JS; Moran EE; Brandt BL Antonie Van Leeuwenhoek; 1987; 53(6):403-11. PubMed ID: 3130779 [TBL] [Abstract][Full Text] [Related]
13. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Maslanka SE; Gheesling LL; Libutti DE; Donaldson KB; Harakeh HS; Dykes JK; Arhin FF; Devi SJ; Frasch CE; Huang JC; Kriz-Kuzemenska P; Lemmon RD; Lorange M; Peeters CC; Quataert S; Tai JY; Carlone GM Clin Diagn Lab Immunol; 1997 Mar; 4(2):156-67. PubMed ID: 9067649 [TBL] [Abstract][Full Text] [Related]
14. Opc- and pilus-dependent interactions of meningococci with human endothelial cells: molecular mechanisms and modulation by surface polysaccharides. Virji M; Makepeace K; Peak IR; Ferguson DJ; Jennings MP; Moxon ER Mol Microbiol; 1995 Nov; 18(4):741-54. PubMed ID: 8817495 [TBL] [Abstract][Full Text] [Related]
15. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Jones DM; Borrow R; Fox AJ; Gray S; Cartwright KA; Poolman JT Microb Pathog; 1992 Sep; 13(3):219-24. PubMed ID: 1283998 [TBL] [Abstract][Full Text] [Related]
16. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. Scholten RJ; Kuipers B; Valkenburg HA; Dankert J; Zollinger WD; Poolman JT J Med Microbiol; 1994 Oct; 41(4):236-43. PubMed ID: 7523677 [TBL] [Abstract][Full Text] [Related]
17. The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Kahler CM; Martin LE; Shih GC; Rahman MM; Carlson RW; Stephens DS Infect Immun; 1998 Dec; 66(12):5939-47. PubMed ID: 9826376 [TBL] [Abstract][Full Text] [Related]
18. Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response. Andersen SR; Bjune G; Høiby EA; Michaelsen TE; Aase A; Rye U; Jantzen E Vaccine; 1997 Aug; 15(11):1225-34. PubMed ID: 9286048 [TBL] [Abstract][Full Text] [Related]
19. Production and characterization of monoclonal antibodies to type 8 lipooligosaccharide of Neisseria meningitidis. Gu XX; Tsai CM; Karpas AB J Clin Microbiol; 1992 Aug; 30(8):2047-53. PubMed ID: 1380009 [TBL] [Abstract][Full Text] [Related]